Marsala Biotech Inc. is a new drug discovery and development company, concentrating on novel treatments for cancer.
Marsala Biotech Inc. is a new drug discovery and development company, concentrating on innovative treatments for cancer. The Company's lead technology, E10A, is an investigational gene therapy agent that utilizes an adenovector to deliver the endostatin gene. E10A is being evaluated in patient populations to treat head and neck cancer. Marsala Biotech Inc. recently completed a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) for the Phase III clinical trial of E10A for head and neck cancer which Marsala plans to initiate in 2016 across North America and Europe.